Higashi-ibaraki, Japan

  • AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

    Phase

    1/2

    Span

    407 weeks

    Sponsor

    AbbVie

    Wako, Saitama

    Recruiting

  • Phase III Trial of Stage I Ovarian Cancer After Surgery

    Based on the following adjustment factors, patients will be randomly assigned in a 1:1 ratio to adjuvant chemotherapy or observation groups. 1. Histologic type: clear cell adenocarcinoma/mucinous adenocarcinoma vs. serous adenocarcinoma/other histologic types 2. Facility where a subject is enrolled 3. International Federation of Gynecology and Obstetrics(FIGO) clinical staging: Stage Ia/ Ib vs. Stage Ic(b) Group A: adjuvant chemotherapy group (standard treatment group): While one of the following treatments will be performed, the number of cycles is entrusted to the treatment policy of each facility. Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles Docetaxel plus Carboplatin (DC) therapy; Docetaxel(DTX) 70 mg/m2 + CBDCA AUC 6 q3weeks day1, 3 to 6 cycles After the start of TC therapy, switching from PTX to DTX due to an adverse event is permitted. Group B: observation group (study treatment group): Observation only, no adjuvant chemotherapy administered.

    Phase

    3

    Span

    915 weeks

    Sponsor

    Japanese Gynecologic Oncology Group

    Wako, Saitama

    Recruiting

  • A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

    Phase

    3

    Span

    314 weeks

    Sponsor

    Eli Lilly and Company

    Wako, Saitama

    Recruiting

1-3 of 3